Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood filter ease chronic fatigue? new trial tests it

NCT ID NCT05710770

Disease control Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a procedure called immunoadsorption — which filters certain antibodies out of the blood — can reduce fatigue in people with chronic fatigue syndrome (ME/CFS), including those whose condition started after COVID-19. Sixty-six adults received either five real treatments or sham (fake) treatments over 10 days, then were followed for six months. The main goal was to see if fatigue scores improved at three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Immunoadsorption (a blood-filtering procedure that removes antibodies)
What this could lead to
If it works, this could point toward a new treatment option for chronic fatigue syndrome, including cases triggered by COVID-19.
What could go wrong
This is a small, early-stage trial with only 66 participants. The treatment requires a catheter and may cause side effects like accidental artery puncture. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

66 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects of all genders ≥18 \<65 years at time of informed consent * Diagnosed ME/CFS according to Canadian consensus criteria (CCC) 2003 including patients with PACS-CFS at screening with Bell Score ≥20 and ≤50 * Detection of at least one kind of autoantibodies measured during screening (among others antineuronal-, ß2-adrenergic-receptor-, muscarine-receptorantibodies) in serum or CSF Exclusion Criteria: * Comorbidity bearing risk that patient might not tolerate treatment as judged by investigator including among others: * malignant disease within the last 5 years * clinically meaningful laboratory abnormalities * moderate to severe renal insufficiency * cardiac insufficiency with an LVEF lower than 40%, uncontrolled cardiac arrhythmia, severe coronary heart disease * severe Hypercoagulability * Acute or severe psychiatric disease * Current indispensable medication with ACE inhibitors * Fatigue duration for ≥5 years * Presence of other conditions or differential diagnosis better explaining the symptoms of the patient than the suspected ME/CFS * Ongoing immunosuppressive therapy * Active/acute infectious diseases like TBC, HIV, CMV, EBV, HBV, HBC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Me/CFS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Me/CFS Post-COVID me/CFS

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.